This grant, offered by the National Cancer Institute (NCI) of the NIH, is for establishing Serological Sciences Centers of Excellence. Its purpose is to advance research on immune responses to SARS-CoV-2 infection. Key objectives include characterizing serological, humoral, and cellular immune responses, understanding mechanisms, and identifying host and environmental modifiers. The grant also aims to determine serological correlates of disease pathogenesis and protection, and to define barriers related to SARS-CoV-2 serological testing. Successful U54 multi-component applicants will join the Serological Sciences Network (SeroNet), fostering collaboration and data sharing across network components.
Opportunity ID: 327535
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-20-038 |
| Funding Opportunity Title: | Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 05, 2020 |
| Last Updated Date: | Jun 05, 2020 |
| Original Closing Date for Applications: | Jul 22, 2020 |
| Current Closing Date for Applications: | Jul 22, 2020 |
| Archive Date: | Aug 27, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Small businesses State governments Public and State controlled institutions of higher education Special district governments Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses County governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies . The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U54 Centers will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Research Projects (U01), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC) and a Serological Sciences Network Coordinating Center (SSNCC) which will be managed through Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. This FOA solicits multi-component U54 Center applications, whereas the companion FOA, RFA-CA-20-039, solicits applications for discrete U01 research projects. Successful applicants from both FOAs will become members of the Serological Sciences Network. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-038.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00262075 | Jun 22, 2020 | Jul 22, 2020 | View |
Package 1
Mandatory forms
327535 RR_SF424_2_0-2.0.pdf
327535 PHS398_CoverPageSupplement_5_0-5.0.pdf
327535 RR_OtherProjectInfo_1_4-1.4.pdf
327535 PerformanceSite_2_0-2.0.pdf
327535 RR_KeyPersonExpanded_2_0-2.0.pdf
327535 PHS398_ResearchPlan_4_0-4.0.pdf
327535 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
327535 PHS_Additional_IndirectCosts-1.0.pdf
327535 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
